<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content

Biliary Tract Cancer PDX Models 
A Champions Model Cohort

An advanced cohort of well-characterized Biliary Tract Cancer (Gallbladder & Cholangiocarcinoma) PDX models directly established from late-stage primary and metastatic tumors available for drug development research.

 Clinically Relevant Models

Living & diverse bank of clinically relevant models that correlate with clinical outcomes

Pretreated PDX Models

Established from tumor biopsies from patients pretreated with latest generation therapies

Multi-omic Characterization

Clinical annotations coupled with molecular datasets and in vivo responses 

Advance your Biliary Tract Cancer Therapies

Biliary tract cancers (BTCs) pose considerable therapeutic challenges due to their aggressive progression and limited treatment options. To advance research and drug development, Champions has established a distinctive cohort of 20* patient-derived xenograft (PDX) models, representing gallbladder cancer and cholangiocarcinoma. These clinically relevant models are derived from patients with advanced, metastatic BTCs who have undergone multiple lines of treatment, including chemotherapy, targeted therapy, and immunotherapy, while preserving key molecular characteristics and driver mutations.  (*Model numbers fluctuate as our dataset continuously evolves.)

Champions' premier biliary tract models cohort showcases low-passage models, each reflecting key clinical characteristics, mutations, and pretreatment history. 

  • Access to a robust bank of biliary tract cancer PDX models with clinically relevant molecular
    and pathological characteristics. 
  • Access to highly characterized PDX models with High Complexity Flow Cytometry, WES, RNAseq, Proteomics, and Phosphoproteomics.
  • Includes models pretreated with advanced therapies like Cisplatin, Epirubicin, Capecitabine, and more.